Cardiol Therapeutics Inc.   Report issue

For profit Phase 3
Founded: Oakville CA United States (2017)

Organization Overview

First Clinical Trial
2020
NCT04615949
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Cardiol Therapeutics Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

cannabidiol (Epidiolex) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cardiovascular Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 1